Anautin

Quick links to important sections

Anautin

Method of action: Antiemetic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anautin

Quick Facts

Property Description
Active ingredient Dimenhydrinate
Form Tablet, Oral solution
Pharmacological class H1-receptor antagonist; Anti-emetic
Common use Prevention and relief of motion sickness symptoms
Origin Synthetic substance

Defining Anautin: Drug Identity and Pharmacological Class

Anautin is a preparation whose active component is the substance Dimenhydrinate, a synthetic compound utilized primarily for its anti-motion sickness properties. The drug is classified as a first-generation H1-receptor antagonist, which places it within the broader class of antihistamines. Unlike agents focused on allergy relief, Dimenhydrinate belongs to the subclass of anticholinergic antiemetics, targeting the central nervous system to reduce sensory input that triggers nausea. Dimenhydrinate suppresses vestibular stimulation, an action utilized for preventing nausea and vomiting. This medicine works by calming the body's balance system, which helps stop feelings of sickness before they start.


Composition and Available Pharmaceutical Forms

The chemical structure of Dimenhydrinate is a unique pharmacological combination—specifically, a salt formed by the union of two distinct molecules: diphenhydramine and 8-chlorotheophylline. Diphenhydramine provides the primary therapeutic effect by acting on histamine receptors, while 8-chlorotheophylline, a xanthine derivative, is included to mitigate the marked sedative-hypnotic effects inherent to the antihistamine component. This dual-component nature defines the drug's distinctive composition. Dimenhydrinate is utilized for its anti-emetic properties in treating motion sickness. As such, the medicine is a recognized option for controlling motion-related sickness. Anautin is typically formulated for systemic use and is available in dosage forms, such as the tablet and the oral solution, intended for administration via the oral route.


General Purpose: What is Anautin Used For?

The fundamental general purpose of Anautin is to prevent and relieve symptoms associated with disturbances to the body’s equilibrium. For instance, it is often used by individuals who experience discomfort during travel by car, boat, or airplane. The drug achieves this by exerting a direct depressant action on the hyperstimulated labyrinthine function. This action translates into the relief of three core symptoms: nausea, vomiting, and vertigo, which frequently arise from motion sickness or specific conditions affecting the inner ear, such as labyrinthine disorders. By suppressing the transmission of over-stimulation from the balance organ to the brain's vomiting center, Dimenhydrinate stabilizes the patient’s sensory perception of motion.

Regulatory References

  1. Dimenhydrinate - LiverTox - NIH
  2. Dimenhydrinate Prescribing Information - DailyMed (NIH/FDA)

What side effects are possible with Anautin?

Possible Side Effects and Safety Information

The safety profile of Anautin (Dimenhydrinate) is officially defined by government regulatory documents, focusing primarily on adverse reactions related to its central nervous system (CNS) and anticholinergic effects. These documents classify possible effects based on physiological systems and expected frequency.

Documented Adverse Reactions

The most frequent adverse reactions listed in official labeling are:

  • Drowsiness/Somnolence
  • Dizziness
  • Dry mouth, nose, and throat
  • Blurred vision
  • Lassitude (fatigue)

Adverse reactions are also classified across several System-Organ Classes, including Nervous System Disorders (e.g., confusion, tremor, excitation), Cardiac Disorders (e.g., tachycardia, palpitations), Gastrointestinal Disorders (e.g., anorexia, stomach upset), and Renal/Urinary Disorders (e.g., urinary difficulty).

Serious Reactions and Safety Constraints

Official labeling notes that severe overdosage may lead to serious adverse reactions, including convulsions, coma, and respiratory depression. The potential for severe allergic reactions is also acknowledged.

Specific safety statements are included for certain populations and conditions:

  • Pediatric Patients have a documented risk of paradoxical excitation rather than sedation, and greater susceptibility to serious overdose effects.
  • Older Adults (Age 60+ ) are noted to be more likely to experience dizziness, sedation, and hypotension.
  • Caution is advised in individuals with pre-existing conditions sensitive to anticholinergic effects, such as narrow-angle glaucoma or prostatic hypertrophy.

Safety documents also state that tolerance to the CNS depressant effects may develop after a few days of treatment and that the substance may mask symptoms of ototoxicity when administered with certain other medications.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Dimenhydrinate (Anautin) is defined by clinical manifestations stemming from severe Central Nervous System (CNS) and anticholinergic toxicity, as documented in official regulatory sources. The officially documented clinical signs of overdose include CNS excitation, which may present as agitation, delirium, confusion, and hallucinations. Peripheral anticholinergic effects are also noted, such as dilated pupils, dry mouth, and hyperpyrexia (severe fever), alongside tachycardia (rapid heartbeat).

Regulatory guidance emphasizes that severe or life-threatening outcomes may occur. These documented severe manifestations include generalized seizures or convulsions, profound respiratory depression, and potential progression to coma or cardiovascular collapse. Children are noted in regulatory labeling to be particularly susceptible to the CNS excitation effects, including convulsions.

Immediate medical attention is required for any suspected overdose. Official regulatory statements mandate that emergency medical services must be contacted immediately if the individual experiences a seizure, has trouble breathing, or exhibits loss of consciousness. Management is described as symptomatic and supportive treatment, often requiring continuous monitoring, such as an ECG, and procedural steps like the administration of activated charcoal or gastric emptying.

Therapeutic Uses of Anautin

Quick Facts

  • Primary Use: May help with symptoms related to motion sickness.
  • Benefit: May assist in managing nausea, vomiting, and dizziness.
  • Additional Use: May be prescribed for the management of inner ear disorders, such as Meniere's disease.

Anautin (often identified by its generic name, dimenhydrinate) is indicated for use in managing symptoms associated with travel and motion-induced discomfort. It is an approved medication that may help to prevent or relieve the symptoms of motion sickness.

Therapeutic use involves the management of specific symptoms, including nausea, vomiting, and dizziness that can arise from motion. By addressing these symptoms, the medication may support comfort and function during activities where motion is a factor.

Furthermore, Anautin may be prescribed by a healthcare provider for certain inner ear problems, such as Meniere's disease, which involves symptoms like extreme dizziness and balance loss. However, its approved indications primarily focus on motion sickness.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Anautin

The eligibility for using Anautin (Dimenhydrinate) is determined by official regulatory criteria, which define both permitted populations and absolute contraindications.

Scope Regulatory Classification
Populations Allowed Adults and adolescents (12+); Children above the minimum age threshold (e.g., 2 years) under the direction of a clinician.
Populations Not Recommended Patients who are breastfeeding or those in the third trimester of pregnancy. Patients with severe hepatic impairment.
Populations Contraindicated Individuals with a known hypersensitivity to the drug or its components. Children under two years of age. Patients with acute angle-closure glaucoma or porphyria.

Condition-Specific Eligibility Rules

Use is restricted and requires caution in older adults and those with specific pre-existing conditions, including epilepsy or seizure disorders, severe cardiovascular disease, severe prostatic hypertrophy, and pyloroduodenal obstruction.

Connection to the overall eligibility profile

Regulatory documents establish strict boundaries by formally contraindicating use for certain populations, such as infants under two and individuals with specific diseases like glaucoma. For other groups, the medicine is explicitly not recommended (e.g., in lactation), thereby defining who is ineligible for use under standard labeled conditions.

What should I know about interactions with other medicines?

The official regulatory profile for dimenhydrinate is defined by several interaction categories, including formal prohibitions and the potentiation of effects. Co-administration with other preparations containing Diphenhydramine is strictly contraindicated due to the risk of increased exposure and toxicity.

A major interaction domain involves additive pharmacodynamic effects. Concurrent use with Alcohol or other Central Nervous System (CNS) Depressants, such as opioids, sedatives, or hypnotics, results in enhanced sedation, drowsiness, and impaired psychomotor performance. Similarly, combining with Anticholinergic Drugs (e.g., tricyclic antidepressants) may potentiate anticholinergic side effects.

Dimenhydrinate may mask the early symptoms of ototoxicity caused by co-administered ototoxic agents, such as aminoglycoside antibiotics, which prevents timely detection of hearing or balance damage. A procedural restriction requires the drug to be discontinued for a specified period prior to diagnostic skin tests to avoid interference with the test results. Furthermore, the drug is a documented inhibitor of the CYP2D6 enzyme, a metabolic pathway, suggesting a potential for increased systemic exposure of co-administered CYP2D6 substrates. In a population-specific restriction, injectable formulations containing benzyl alcohol are contraindicated for use in neonates and premature infants.

Mechanism of Action

Central Vestibular Pathway Depression via Receptor Blockade

The mechanism of Anautin operates through Central Vestibular Depression (CVD). The primary active component functions as a competitive antagonist at central Histamine H1 receptors and Muscarinic Acetylcholine Receptors in the brainstem. By blocking these neurotransmitter targets, the drug reduces the activity of neurons in the vestibular nuclei, which are critical relay points for motion and balance information coming from the inner ear. This targeted receptor blockade modifies the molecular steps that precede and drive the reflex arc.


Modulating the Reflex Arc Cascade

This resulting Central Vestibular Depression (CVD) leads to the reduction of activity within the reflex arc. The lowered excitatory input from the vestibular pathway means that the brainstem structures that coordinate the reflex receive significantly fewer signals of motion disturbance. This physiological change modulates activity within the balance control pathways, restricting the signal propagation of vestibular input to the brainstem.


Pharmacodynamic Counterbalance (Synergy)

Anautin is a salt combination that includes 8-chlorotheophylline, which acts as an antagonist at Adenosine Receptors in the CNS. This secondary mechanism introduces a mild stimulating effect that physiologically modulates the pronounced H1-receptor-driven CNS depressant properties of the primary active component. This ensures that the receptor blockade is achieved alongside a modulation of overall CNS depressant effects.

Dosage and Administration Information

Instruction Map: How to use Anautin

Field Description
Route of administration The medication is utilized via Oral (tablet, solution), Intramuscular (IM), Intravenous (IV), and Rectal routes.
Dosing schedule (Adults, Oral IR) A single dose is typically 50 mg to 100 mg. The Maximum Daily Dose must not exceed 400 mg in a 24-hour period.
Timing in relation to meals Dimenhydrinate may be taken with or without food.
Preparation requirements For Intravenous (IV) administration, the 50 mg dose must be diluted (e.g., in 10 mL of 0.9% sodium chloride) before administration.
Age-group administration rules Tiered dosing applies to pediatric groups. For example, children aged 6 to under 12 typically use 25 mg to 50 mg per dose, with a maximum of 150 mg daily.
Missed-dose rules The general practice for a missed dose is to take it as soon as remembered if still necessary; however, taking two doses at the same time is cautioned against.
Special procedural conditions The first dose is taken 30 minutes to 1 hour before the start of the activity for preventive use. IV administration is performed slowly, typically over two minutes.

Instruction classifications (high-level)

Field Classification
Administration method type Multi-route (Oral, IV, IM, Rectal)
Frequency pattern As-needed (PRN), repeated every 4 to 6 hours for immediate-release forms.
Use-context constraints Requires specific pre-exposure timing for prophylaxis.

Resulting procedural structure

Step sequence:

  • Administer the medicine via the appropriate route (Oral, IV, IM, or Rectal) as needed.
  • For prevention, the dose is administered 30 minutes to 1 hour before exposure to motion.
  • The dose may be repeated every 4 to 6 hours as required, ensuring the 400 mg maximum daily limit is not surpassed.

Connection to the overall use protocol (2–4 sentences): The instructions establish a structured protocol centered on as-needed administration with defined dosage limits and timing constraints for prophylactic use. These parameters dictate specific preparation and rate requirements for parenteral routes, ensuring standardized practice when non-oral forms are utilized. They also provide a clear, age-dependent dosage schema for use across different pediatric groups.

Recent Clinical Evidence

Research evidence / Overview of studies for Anautin


Evidence for use in Motion Sickness

Studies explored the use of Anautin (dimenhydrinate) in trials assessing short-term or episodic symptom patterns, such as those related to motion sickness, a condition characterized by fluctuating manifestations of nausea, vomiting, and dizziness. Research focusing on short-term symptom changes primarily consists of Randomized Controlled Trials (RCTs), including those comparing the compound against a placebo or other active anti-emetic medications.

These trials were observed in healthy adults, naval personnel, and pediatric populations. The primary outcomes related to physical discomfort were monitored by measuring the percentage of participants who developed symptoms and the variability of those symptoms using patient-reported outcomes describing perceived discomfort. Findings describe the patterns observed in the studies concerning the frequency of motion sickness development across different groups during short-term motion exposure.

Evidence for use in Vertigo and Associated Nausea

Anautin was evaluated in research exploring temporary physiological imbalance, specifically as it was studied for symptoms related to vertigo and the associated outcomes related to systemic or functional imbalance. Studies examined the compound’s use in conditions involving periods of heightened symptoms, such as acute vertigo attacks often linked to inner ear disorders. These trials often utilized the compound as part of a fixed-dose combination product.

Findings indicate patterns related to a change in the manifestation of vertigo and associated nausea scores, particularly when the compound was observed in trials of a fixed-dose combination product over intermediate time intervals (e.g., several weeks). Studies help show what has been observed so far in conditions presenting with cycles of stability and flare-ups, specifically concerning episodes where symptoms become more noticeable.

What is Still Uncertain About Anautin

Evidence quality varies across studies, and the long-term effects are not fully established; there is limited information for long-term outcomes, particularly for chronic or repeated use. Research provides limited insight into the isolated effect of the single compound for treating acute vertigo symptoms, as much of the available evidence is derived from fixed-dose combination products. Comparative evidence is lacking against all potential therapeutic and non-pharmacological alternatives for all studied indications.

Key Studies & References

  1. Dimenhydrinate Tablets, USP 50 mg - DailyMed (NIH/NLM official drug label for pediatric and adult use)

Frequently Asked Questions (FAQ)

Common questions about Anautin (FAQ)

Q: Is Anautin the same as other similar treatments I've heard of?

Anautin's active ingredient, dimenhydrinate, is a unique salt that combines two components. The combination includes the anti-sickness component, diphenhydramine, and a second component, 8-chlorotheophylline, which is included to modulate the sedative properties inherent in the primary active part of the medicine.

Q: How quickly does Anautin start working?

According to national drug information, when Anautin is taken by mouth, the effects typically begin in about 30 minutes. This quick onset is a feature noted for preventive use, which is why official instructions often advise taking it shortly before activity begins.

Q: How long does the effect of Anautin last after taking it?

Following oral administration, the effects of the medication generally last for 3 to 6 hours. This duration of effect is consistent with the official instruction that doses may be repeated every 4 to 6 hours as needed.

Q: Why do people say they feel tired when they start taking Anautin?

Drowsiness or somnolence is the most frequent adverse reaction listed in official labeling for Anautin. This common effect is related to the drug’s primary action as a Histamine H1-receptor antagonist in the central nervous system (brain), which reduces activity in these pathways.

Q: Is Anautin approved for use in children?

Regulatory documents permit the use of Anautin for children who are above a minimum age threshold, such as two years, but use must be directed by a clinician. Official prescribing information includes explicit age-dependent dosing instructions that apply to pediatric patient groups.

Q: Does Anautin have a risk of dependence or addiction?

Official information notes that a tolerance to the central nervous system (CNS) depressant effects may develop after a few days of treatment. Separately, case reports associated with heavy, high-dose use of the drug have indicated a potential for dependence.

Q: Can Anautin be taken with vitamin supplements?

Official drug documents focus on interactions with other medicines, alcohol, and herbal supplements. While common vitamin supplements are not formally restricted, non-authoritative interaction databases generally list no major known interactions. A discussion with a healthcare provider may be required for specific needs.

Q: What is the experience of patients who have used Anautin for a long time?

Studies and research evidence indicate that there is limited information regarding long-term outcomes for this medicine. The effects of chronic or repeated use of the single compound are therefore not fully established in the available evidence base.

Q: What happens if I accidentally take too much Anautin?

Severe overdosage may lead to serious adverse reactions, which include convulsions, coma, and respiratory depression. Regulatory resources advise that in the case of a suspected overdosage, an immediate call to a poison control center or emergency medical services is recommended.

Q: What is the maximum amount of time Anautin is generally taken for?

Anautin is classified for as-needed use to treat short-term or episodic symptoms. The long-term effects of chronic or repeated use are currently noted as not fully established by the available research evidence.

Q: Do I need a special diet while taking Anautin?

Official instructions state that the medicine may be taken with or without food. There are no specific special dietary restrictions or requirements listed in the regulatory labeling for Anautin.

Q: What should I do if a side effect is bothering me?

Patient information from authoritative sources generally advises reporting any side effects that are bothersome or concerning to a healthcare provider for review.

Q: Does taking Anautin mean I can't drive or operate machinery?

Official warnings state that due to the potential for drowsiness and impaired coordination, use of this medication may require avoiding driving or operating heavy machinery. This caution is advised until a person knows how the medication affects them.

Q: Is Anautin a controlled substance?

Anautin is widely available as an over-the-counter (OTC) medication in many countries. It is not listed as a scheduled controlled substance in primary regulatory databases.

Q: Are there any known long-term side effects associated with Anautin?

Long-term effects are not fully established by current research evidence. Official safety documents address risks related to prolonged use, such as the potential for tolerance to the CNS depressant effects to develop.

Q: How does Anautin affect my liver or kidneys?

Official regulatory guidance does not provide specific dose adjustments for renal or hepatic function. One authoritative source notes that the drug has not been linked to instances of clinically apparent acute liver injury.

Q: Are there different strengths or formulations of Anautin available?

The medication is available in high-level dosage forms, such as the tablet and the oral solution. Common strengths, such as the 50 mg tablet, are referenced in official labeling.

Q: How long does Anautin stay in my system?

Pharmacokinetic data suggests the primary active component (diphenhydramine) in adults has a terminal half-life of approximately 9.2 hours.

Q: If I feel better, can I stop taking Anautin?

The medication is classified for use on an as-needed (PRN) basis for episodic symptoms. Official prescribing information often advises taking a dose only if it is still considered necessary or if symptoms are still present.

Q: What happens if Anautin doesn't seem to be working for me?

Patient information generally advises consulting a healthcare provider if there are questions about the effectiveness of the medicine or if symptoms persist.

Q: Why is Anautin sometimes prescribed for different conditions?

The official uses relate to disturbances of equilibrium, which include motion sickness, nausea, vomiting, and vertigo. Some authoritative sources also note its use for inner ear conditions that cause extreme dizziness, such as Meniere’s disease.

Q: Does Anautin cause changes in mood or behavior?

Official labeling notes adverse reactions in the Nervous System Disorders class, which include confusion, tremor, and excitation. These effects may involve noticeable changes in behavior or overall mood.

Q: Can people with high blood pressure take Anautin?

Regulatory documents advise caution for individuals with pre-existing conditions that are sensitive to anticholinergic effects, such as severe cardiovascular disease or cardiac arrhythmias. A discussion with a healthcare provider is generally advised before use in such populations.

Q: Does Anautin interfere with lab tests?

Official documents state that the drug must be discontinued for a specified period prior to diagnostic skin tests to avoid interference with the test results.

Q: Is the medication Anautin considered a high-risk drug?

The official regulatory profile does not use the term “high-risk.” Safety constraints define documented risks, such as the potential for severe adverse reactions if overdosage occurs, including convulsions and respiratory depression.

Q: Can Anautin be crushed or split?

The physical manipulation of dosage forms is not explicitly defined for all formulations. Non-chewable oral tablets are typically intended to be swallowed whole unless explicit instructions for crushing or splitting are provided by the manufacturer.

Q: How do I know if Anautin is right for my condition?

Patient information generally advises discussing the use of the medicine with a healthcare provider, especially when pre-existing medical conditions are present.

Q: What is the recommended approach if a known side effect occurs?

Patient information generally advises reporting any concerning side effects to a healthcare provider. They can advise on how to report or manage the side effect.

Q: Are there any common allergies or sensitivities to the ingredients in Anautin?

The drug is formally contraindicated for individuals with a known hypersensitivity to the drug or its components. A discussion with a healthcare provider about the medicine's ingredients is advised if known allergies are present.

How should Anautin be stored and disposed of?

Storage and Disposal Requirements for Anautin (Dimenhydrinate)

Official regulatory guidelines define precise conditions for storing and disposing of Dimenhydrinate to maintain its stability and effectiveness.


Required Storage Conditions

  • Temperature: The medication must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Temporary variations are permitted between 15 C and 30 C.
  • Protection: The injectable solution must be stored with protection from light. Tablets must be kept in a tightly closed container and stored in the original container.
  • Child Safety: All forms of the product must be stored out of the sight and reach of children.

Disposal

Follow any specific disposal instructions provided on the official drug labeling. If no special instructions are given, regulatory bodies recommend mixing unused medicine with an unappealing substance, placing it in a sealed container, and discarding it in the household trash, rather than flushing it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anautin found in:

A-Z Index: